Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
12548
Shown on this page
12
Current sort
Recently updated
Location scope
Miami, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Miami, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 889–900 of 12,548 matching trials in Miami, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting No phase listed Observational

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
Not listed
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
19
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Active, not recruiting Phase 2 Interventional

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

NCT05995964
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-07275315, PF-07264660, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Recruiting Phase 3 Interventional

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions
daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

NCT06874621
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
VY7523, Placebo Comparator
Drug
Lead sponsor
Voyager Therapeutics
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Recruiting Phase 3 Interventional

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

NCT06094010
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Weeks to 11 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Not yet recruiting Phase 2 Interventional

VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study

NCT07891182
View directory record Official record
Conditions
Glaucoma
Interventions
Aflibercept Injection, Ahmed Tube Surgery
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

NCT05489614
View directory record Official record
Conditions
Renal Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Rialto, California • Yucaipa, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

NCT07453602
View directory record Official record
Conditions
Atopic Dermatitis (AD), Eczema
Interventions
ARQ-234, Placebo
Biological · Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
7
States / cities
Miami, Florida • Plainfield, Indiana • Fair Lawn, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Recruiting Phase 3 Interventional

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07184996
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
120
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Active, not recruiting Phase 3 Interventional

S0820, Adenoma and Second Primary Prevention Trial

NCT01349881
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2032
U.S. locations
989
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
342
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST
Recruiting Phase 2 Interventional

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

NCT05366816
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Sunitinib, Regorafenib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 11:11 AM EST